Annual report pursuant to Section 13 and 15(d)

Derivative Contracts (Details)

v2.4.0.8
Derivative Contracts (Details) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Jan. 30, 2013
Dec. 31, 2012
Derivatives, Fair Value [Line Items]      
Convertible senior notes interest rate 3.00%    
Notes [Member] | Notes Due February 1, 2033 [Member]
     
Derivatives, Fair Value [Line Items]      
Convertible senior notes interest rate 3.00% 3.00% 3.00%
Not Designated as Hedging Instrument [Member] | Pharmsynthez Notes Receivable and Purchase Option [Member] | Prepaid expenses and other current assets [Member]
     
Derivatives, Fair Value [Line Items]      
Derivative asset, fair value $ 6,151   $ 0
Not Designated as Hedging Instrument [Member] | Neovasc common stock options/warrants [Member] | Investments [Member]
     
Derivatives, Fair Value [Line Items]      
Derivative asset, fair value 5,988   1,872
Not Designated as Hedging Instrument [Member] | Embedded conversion option [Member] | 3.00% convertible, senior notes, net of discount and estimated fair value of embedded derivatives [Member]
     
Derivatives, Fair Value [Line Items]      
Derivative liability, fair value 101,087   0
Not Designated as Hedging Instrument [Member] | Forward contracts [Member]
     
Derivatives, Fair Value [Line Items]      
Derivative liability, fair value 1,585   1,294
Not Designated as Hedging Instrument [Member] | Forward contracts [Member] | Current portion of lines of credit and notes payable [Member]
     
Derivatives, Fair Value [Line Items]      
Derivative liability, fair value $ 1,585 [1]   $ 1,294 [1]
[1] The loss on forward contracts is recorded in Accrued expenses. The gain on the forward contracts is recorded in Prepaid expenses and other current assets.